pharmaceuticals

MDPI

Article

Fibrinogen-Driven NLRP3 Inflammasome: A Novel Therapeutic Target for Tong-Qiao-Huo-Xue Decoction in Ischemic Stroke

Yan Wang [1,†], Yuqin Peng [2,†], Hao Sun [2], Kai Zhu [2], Ning Wang [2,*] and Changzhong Wang [1,*]

[1] Department of Pathogenic Biology and Immunology, College of Integrated Chinese and Western Medicine, Anhui University of Chinese Medicine, Hefei 230012, China; yanwangsci@163.com
[2] Institute for Pharmacodynamics and Safety Evaluation of Chinese Medicine, Anhui Academy of Chinese Medicine, Hefei 230012, China; pyqedu@163.com (Y.P.); azysunhao@163.com (H.S.); zkazsy@163.com (K.Z.)
* Correspondence: wnsci123@163.com (N.W.); ahwcz63@sina.com (C.W.)
† These authors contributed equally to this work.

Abstract

Background: Plasma fibrinogen (FIB) levels exhibit a significant elevation during the acute phase of ischemic stroke (IS), and their dynamic fluctuations serve as important biomarkers for stroke onset, disease progression, and long-term prognosis. Tong-Qiao-Huo-Xue Decoction (TQHXD) is highly effective in treating blood stasis syndromes affecting the head and face. Nevertheless, the association between TQHXD and FIB in the underlying mechanism of treating IS warrants further investigation. **Methods**: Proteomics analysis predicted the potential therapeutic targets of TQHXD for IS. An in vivo model of middle cerebral artery occlusion followed by reperfusion (MCAO/R) was created in mice. To explore the interaction between FIB and NLRP3, as well as to verify the particular healing outcomes of TQHXD. **Results**: An increased blood–brain barrier (BBB) permeability was observed after MCAO/R, accompanied by substantial accumulation of FIB in the brain. In vivo experiments demonstrated that FIB triggered the activation of the NLRP3 inflammasome in microglia. Proteomic analysis revealed a significant increase in FIB levels following model induction, which were markedly reduced after treatment with TQHXD; KEGG pathway enrichment analysis indicated that these changes were primarily associated with the NOD-like receptor signaling pathway. Laser speckle contrast imaging showed that TQHXD treatment significantly improved cerebral blood flow and attenuated brain injury in mice. Fluorescence imaging, ELISA, and Western blotting results collectively demonstrated that TQHXD effectively reduced FIB accumulation and suppressed NLRP3 inflammasome activation. MD and pull-down experiments further demonstrated a strong interaction strength between FIB and NLRP3. **Conclusions**: FIB accumulates in the ischemic penumbra following CIRI, while TQHXD can effectively down-regulate FIB expression and inhibit NLRP3 inflammasome activation to mitigate CIRI. These findings provide a novel theoretical foundation and treatment direction for stroke management in clinical settings.

Keywords: ischemic stroke; TQHXD; fibrinogen; NLRP3; MCAO/R

Academic Editor: Réjean Couture

Received: 4 January 2026
Revised: 8 February 2026
Accepted: 13 February 2026
Published: 15 February 2026

1. Introduction

Ischemic stroke (IS) is a sudden-onset cerebrovascular event disorder resulting from stenosis or occlusion of cerebral arteries, including the common carotid artery or vertebral artery, leading to brain tissue necrosis due to insufficient blood flow. It constitutes more than 80% among all instances of stroke and is linked to a high risk of disability and mortality, thereby posing a significant risk to public health [1]. Optimizing the management of

IS in clinical practice mainly encompasses the establishment of dedicated stroke units, intravenous thrombolysis for eligible patients, and endovascular mechanical optimize blood flow restoration through thrombectomy in occluded vessels. However, the practical application of these interventions is limited by a restricted therapeutic window and the occurrence of severe inflammatory complications. As a result, fewer than 5% of patients qualify for thrombolytic therapy, and only approximately 10% achieve a favorable clinical outcome following treatment [2].

Candelario-Jalil E et al. have demonstrated that the inflammatory response following a stroke is a prolonged pathological process that plays an important part in the development of secondary brain damage after cerebral ischemia–reperfusion injury (CIRI) [3]. This process is closely linked to the activation of microglia and the NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome complex [4]. Roseborough et al. have shown that plasma fibrinogen (FIB) is capable of crossing the disrupted blood–brain barrier (BBB) following IS, which triggers the activation of microglia and the NLRP3 inflammasome [5]. Consequently, the regulation of NLRP3 inflammasome activation by FIB has become a potential treatment approach for alleviating inflammatory damage following IS. Research into this target not only provides new insights for the clinical management of IS but also carries significant implications for improving post-stroke rehabilitation outcomes, reducing disability, and preventing mortality.

Traditional Chinese Medicine (TCM) demonstrates considerable potential in this area. IS is recognized as a subtype of stroke in TCM, and is characterized by impaired qi and blood circulation, as well as the presence of extravascular blood stasis. The primary pathological factor involved is "blood stasis." Consequently, the therapeutic principle of "activating blood circulation to resolve blood stasis" is considered a fundamental strategy in the medical treatment of stroke. FIB, as a pivotal substrate in the coagulation cascade reaction, when its concentration increases, can accelerate the aggregation of red blood cells, increase blood viscosity, and accelerate thrombosis formation, which is highly consistent with the symptoms of "blood stasis and blocked meridians" in traditional Chinese medicine. Therefore, the level of FIB can not only be regarded as an objective indicator of the "blood stasis" syndrome but also serve as a molecular target for evaluating the intervention effect of the blood-activating and stasis-resolving method.

Tong-Qiao-Huo-Xue Decoction (TQHXD), an ancient prescription formulated by Qingren Wang during the Qing Dynasty, has been extensively utilized for enhancing blood flow and alleviating blood congestion. This herbal formulation demonstrates therapeutic effects on head and facial symptoms associated with blood stasis. Moreover, clinical evidence supports its effectiveness in managing IS. Previous studies conducted by our research group have demonstrated that TQHXD not only exerts significant neuroprotective effects in rats with IS, but also alleviates BBB damage induced by stroke while promoting neural cell repair [6–8]. Additionally, it demonstrates a protective action in opposition to inflammatory injury by modulating the intestinal microecological imbalance in rats following CIRI [9]. However, the exact mechanism by which TQHXD inhibits neuroinflammation has yet to be fully elucidated. This study is intended to investigate the impact of TQHXD on the level of FIB in the brains of MCAO/R mouse models and further elucidate the role of FIB entry into the brain in the activation of the NLRP3 inflammasome in microglia. This not only contributes to a more in-depth scientific understanding of the "blood stasis-inflammation-nerve injury" pathway but also offers a foundation for the clinical intervention strategy of "anti-inflammation-nerve protection-functional repair". It holds significant theoretical value in reducing the long-term disability and mortality rates of IS, provides modern molecular interpretations for the treatment of IS using the method of promoting blood circulation and removing blood stasis, establishes an experimental basis for the precise

and evidence-based development of integrated traditional Chinese and Western medicine treatment plans, and also furnishes robust experimental evidence for the clinical application and promotion of TQHXD.

2. Results

2.1. NLRP3 Could Be Pulled Down to Interact with FIB

Following the establishment of the CIRI model, a significant increase in FIB levels was observed in both brain tissue and peripheral blood. Lumbrokinase, as a fibrinolytic agent, significantly reduced FIB levels (Figure 1A,B). To confirm the direct interaction between FIB and NLRP3, protein docking was employed for predictive analysis, and pull-down assays were performed using brain tissue from MCAO/R mice to validate the interaction. The protein docking results suggested a potential interaction between FIB and NLRP3 (Figure 1C), which was subsequently validated through a pull-down experiment. Pull-down results (Figure 1K) indicated a strong interaction between NLRP3 and FIB. The complex system shows slight fluctuations (Figure 1D). It is proven that the binding of two proteins will affect the binding microenvironment and lead to a certain degree of change in SASA. Upon the binding of the two proteins (Figure 1E), the quantity of hydrogen bonds between small molecules and the target protein varies from 0 to 14, with 1 to 5 hydrogen bonds commonly observed throughout. This suggests that there exists a continuous yet relatively dynamic hydrogen-bond interaction between them. These hydrogen bonds may serve a crucial function in stabilizing the ligand binding, and their dynamic alterations may mirror a certain level of flexibility or breathing motion at the binding site. As can be observed from Figure 1F, the protein complex experiences conformational changes during the movement. As shown in Figure 1G, the complex system reached equilibrium after 70 ns and ultimately fluctuated around 2 Å. Consequently, these two proteins demonstrate high stability upon binding to each other. The RMSF values of this complex are relatively low (mostly below 4 Å), indicating that it has lower flexibility and higher stability (Figure 1H,I). The red areas in the figure indicate higher free energy, while the blue areas represent lower free energy. From Figure 1J, it can be seen that the complex has lower free energy when the RMSD is 0.18, and the Rg value is 2.31, which may suggest that these conformations are more stable. Additionally, plasma and brain tissue FIB levels were measured at 3, 7, and 14 days post-treatment. The results indicated that the peak inflammatory response occurred on day 7, at which point the therapeutic effect of the drug was most pronounced. Therefore, day 7 was selected as the optimal time point for drug administration and sample collection.

2.2. FIB Plays a Pivotal Role in the Regulation of Neuroinflammation in MCAO/R Mice

Compared with the model group, lumbrokinase treatment led to a significant decrease in neurobehavioral score (Figure 2A) and cerebral infarct volume (Figure 2B,C). The MCAO/R model induces a significant reduction in cerebral blood flow, which can be effectively reversed by Lumbrokinase administration (Figure 2D). Histological analysis showed that lumbrokinase effectively attenuated inflammatory infiltration in the cerebral cortex of MCAO/R-injured mice (Figure 2E).

2.3. FIB Triggers Downstream Activation of NLRP3, Exacerbating Neuroinflammatory Injury

To investigate whether FIB activates the NLRP3 inflammasome and thereby induces pyroptosis, we employed dual immunofluorescence staining to detect GSDMD and NLRP3 expression. The results demonstrated that the MCAO/R model not only upregulated FIB but also significantly increased the fluorescence intensity of NLRP3 and GSDMD (Figure 3A–C), which was further confirmed by Western blot analysis showing elevated protein levels of both markers (Figure 4A,D). Additionally, downstream components of

the inflammasome pathway, including Caspase-1 and ASC (Figure 4B,C), were also upregulated, indicating robust activation of the NLRP3 inflammasome. To determine whether this activation occurred specifically in microglia, dual immunofluorescence staining for NLRP3 and the microglial marker TMEM119 was performed. A substantial degree of colocalization between NLRP3 and TMEM119 fluorescence was observed (Figure 3D–F), with consistent changes in fluorescence intensity, suggesting microglial-specific inflammasome activation. Furthermore, transmission electron microscopy observations indicated that the MCAO/R mice displayed impaired microglial membrane structures, absence of mitochondrial cristae, and significant vacuolar changes (Figure 3G). In contrast, lumbrokinase administration ameliorated these pathological alterations. Activation of the NLRP3 inflammasome promotes the cleavage of pro-IL-18 and pro-IL-1β into their mature (Figure 4E,F), biologically active forms, thereby amplifying neuroinflammatory responses. These changes can be significantly reversed by Lumbrokinase. Notably, similar effects were observed with MCC950 treatment, providing strong evidence that FIB aggregation further promotes downstream inflammasome activation via NLRP3 after MCAO/R injury, thereby exacerbating neuroinflammation.



Figure 1. FIB is involved in the pathological process following CIRI induced by MCAO/R. (**A**,**B**) Lumbrokinase down-regulated the content of FIB in plasma. ((**A**) and brain tissue (**B**) of MCAO/R mice. (n = 6) (**C**) Protein–protein docking results of NLRP3 (blue) and FIB (green) were obtained. (**D**) Solvent accessible surface area. (**E**) Number of hydrogen bonds. (**F**) Radius of Gyration. (**G**) Root-mean-square deviation. (**H**,**I**) Root mean square fluctuation. (**J**) Free Energy Landscape. (**K**) NLRP3 can be pulled down by FIB (n = 3).) ** $p < 0.01$ vs. Sham group; ## $p < 0.01$ vs. Model group.



Figure 2. The FIB mechanism plays a crucial role in the pathogenesis of MCAO/R injury. (**A**) Lumbrokinase reduces neurobehavioral scores in MCAO/R mice. (n = 10). (**B**,**C**) Lumbrokinase reduces cerebral infarct volume in MCAO/R mice. (n = 3) (**D**) Lumbrokinase has been shown to enhance cerebral blood flow. (**E**) Lumbrokinase mitigates inflammatory infiltration in the cerebral cortex of MCAO/R mice (n = 5). ** $p < 0.01$ vs. Sham group; $^{\#\#}$ $p < 0.01$ vs. Model group.

2.4. TQHXD Ameliorates Cerebral Injury in MCAO/R Mice

CIRI may lead to neurobehavioral impairments and brain edema in mice. TQHXD treatment significantly attenuates the increase in cerebral infarction volume (Figure 5C,D), brain edema (Figure 5B), and neurological deficit scores (Figure 5A) induced by MCAO/R. Laser speckle contrast imaging results (Figure 5E,F) further demonstrate that MCAO/R leads to a marked reduction in cerebral blood flow, which is effectively ameliorated by both TQHXD and the positive control drug NBP. Notably, the medium dose of TQHXD (7.7 g/kg) demonstrated the most significant effect, equivalent to the effect observed with the positive control medication NBP.



Figure 3. The involvement of FIB in the regulation of neuroinflammation has been demonstrated. (n = 3). ((**A**–**C**) Expression of GSDMD and NLRP3 fluorescence was quantified by measuring the intensity of fluorescent staining. (**D**–**F**) Expression of TMEM119 and NLRP3 fluorescence was quantified by measuring the intensity of fluorescent staining. (**G**) Lumbrokinase attenuates microglial pyroptosis in MCAO/R mice (n = 3, 500 nm).) ** $p < 0.01$ vs. Sham group; ## $p < 0.01$ vs. Model group.

2.5. Findings from Proteomics Analysis

The Pearson correlation heatmap of proteomics samples in Figure 6A was used to assess the quantitative consistency among biological replicates and the differentiation between groups. All biological replicates exhibited correlation coefficients ≥ 0.96, demonstrating high reproducibility in quantification. Within-group correlations were generally ≥0.98, whereas between-group correlations were slightly lower but still ≥0.96, indicating that the model intervention effectively induced differential protein expression. The protein profile of the TQHXD treatment group showed a shift toward that of the Sham group, suggesting a significant reversal effect of the drug. As shown in the Venn diagram in Figure 6B, a total of 9143 proteins were identified in mouse brain tissue, with 8892 proteins commonly expressed in both the Sham and Model groups. Further analysis of these shared proteins revealed differentially expressed proteins between the Model and Sham groups (Figure 6C). Among the up-regulated proteins, FIB ranked relatively high. As illustrated in the volcano

plot in Figure 6D, FIB was significantly down-regulated in the TQHXD group compared to the Model group. Additionally, functional analysis indicated that TQHXD-mediated repair of brain tissue in MCAO/R-injured mice primarily involved mononuclear macrophages (microglia), as shown in Figure 6E. Time-series clustering of differentially expressed proteins using Mfuzz (k = 5) revealed five distinct expression patterns, as summarized in Figure 6F. Among them, Cluster 4 (n = 74) exhibited a pattern of significant upregulation in the Model group and significant downregulation in the TQHXD group. This cluster was enriched in pathways such as "NF-κB signaling" and "cytoplasmic PRR recognition," indicating that the proteins within this cluster are primarily involved in the initiation of neuroinflammation and may be closely associated with NLRP3 inflammasome activation. Furthermore, KEGG enrichment analysis of the 8937 proteins commonly expressed between the TQHXD and Model groups (Figure 6G) revealed prominent enrichment in the NOD-like receptor signaling pathway, TNF signaling pathway, and apoptosis (pyroptosis)-related pathways. The activation mechanism of the NOD-like receptor signaling pathway and the two-step activation model of the NLRP3 inflammasome (initiation and assembly). Specifically, FIB initially triggers the NF-κB pathway, leading to the transcriptional up-regulation of core proteins such as NLRP3 and pro-IL-1β to complete the initiation stage. Subsequently, through signals like K^+ efflux, ASC is induced and recruited to form a complex, which activates Caspase-1 to mediate the maturation and release of cytokines and pyroptosis. The involvement of these pathways further underscores their functional relevance to NLRP3 inflammasome activation and neuroinflammatory processes.



Figure 4. Expression levels of proteins associated with NLRP3 inflammasome-mediated pyroptosis in brain tissues from the affected hemisphere of mice (n = 3). (**A**): The expression status of NLRP3. (**B**): The expression status of ASC. (**C**): The expression status of caspase-1. (**D**): The expression status of GSDMD. (**E**): The expression status of IL-1β. (**F**): The expression status of IL-18. ** $p < 0.01$ vs. Sham group; $^{\#}$ $p < 0.05$, $^{\#\#}$ $p < 0.01$ vs. Model group.



Figure 5. TQHXD mitigates cerebral ischemia/reperfusion injury in mice. ((**A**) TQHXD enhances the restoration of neurobehavioral function in MCAO/R mice. (n = 10). (**B**) TQHXD effectively mitigates brain edema in mice subjected to MCAO/R. (n = 6). (**C**,**D**) TQHXD leads to a reduction in cerebral infarct volume in mice subjected to MCAO/R. (n = 6). (**E**) TQHXD enhances cerebral blood flow. (**F**) TQHXD facilitates the mapping of quantitative cerebral blood flow.) ** $p < 0.01$ vs. Sham group; # $p < 0.05$, ## $p < 0.01$ vs. Model group.



Figure 6. Analysis results graph of the effect of TQHXD on the expression of differential proteins (n = 3). (**A**): Heatmap of Pearson correlation coefficients among proteomics samples. (**B**): Venn diagram illustrating shared and unique protein sets across groups. (**C**): Volcano plot depicting

differentially expressed proteins between the Sham and Model groups. (**D**): Volcano plot depicting differentially expressed proteins between the Model and TQHXD treatment groups. (**E**): Subcellular localization distribution of identified proteins. (**F**): Hierarchical clustering heatmap of protein expression profiles. (**G**): KEGG pathway enrichment analysis of differentially expressed proteins.

2.6. TQHXD Attenuating Neuroinflammatory Injury Through the Inhibition of FIB

Upon entering the brain parenchyma, FIB can activate the NLRP3 inflammasome in microglia. Immunofluorescence multilabeling analysis revealed that TQHXD significantly decreased the fluorescence intensity of NLRP3, with concomitant reductions in GSDMD expression (Figure 7B–D). Furthermore, colocalization studies confirmed that TQHXD specifically suppressed NLRP3 activation in microglia (Figure 7E–G). Under transmission electron microscopy, following the establishment of the MCAO/R model, microglia exhibited blurred cellular contours, swollen organelles, structural damage, and vacuolar degeneration. The intervention outcomes in the TQHXD treatment group were comparable to those of the earthworm kinase and MCC950 groups, demonstrating a significant amelioration of pyroptosis-related injury in the ischemic penumbra of MCAO/R model mice (Figure 7A).



Figure 7. The down-regulation of FIB by TQHXD attenuates neuroinflammation in MCAO/R mice. (n = 3). ((**A**) TQHXD mitigates microglial apoptosis in mice subjected to MCAO/R. (**B**–**G**) The fluorescence intensity of GSDMD and NLRP3. (**B**–**D**). Fluorescence intensity of TMEM119 and NLRP (**E**–**G**) in the cerebral cortex of MCAO/R mice, attenuated by TQHXD.) ** $p < 0.01$ vs. Sham group; ## $p < 0.01$ vs. Model group.

2.7. The TQHXD Compound Mitigates Injury in MCAO/R Mice by Effectively Suppressing the FIB-NLRP3 Signaling Pathway

WB results demonstrated that TQHXD could significantly inhibit the activation of the NLRP3 inflammasome, as evidenced by reduced expression levels of NLRP3, ASC, and Caspase-1 proteins (Figure 8A–C). Additionally, the expression of GSDMD (Figure 8D), a downstream effector protein of the NLRP3 pathway, was also markedly decreased. Since cellular pyroptosis contributes to the exacerbation of neuroinflammation, the observed reduction in IL-18 and IL-1β protein expression following TQHXD treatment suggests that it effectively mitigates neuroinflammatory responses after cerebral ischemia (Figure 8E,F). These findings indicate that TQHXD exerts neuroprotective effects by inhibiting the activation of the NLRP3 inflammasome, thereby attenuating neuroinflammation and reducing cerebral damage in MCAO/R mice.



Figure 8. The expression of inflammation-related proteins was downregulated by TQHXD, as evidenced by Western blot analysis. ((**A**): The expression status of NLRP3. (**B**): The expression status of ASC. (**C**): The expression status of caspase-1. (**D**): The expression status of GSDMD. (**E**): The expression status of IL-1β. (**F**): The expression status of IL-18.) ** $p < 0.01$ vs. Sham group; ## $p < 0.01$ vs. Model group.

2.8. The Active Components of TQHXD and Their Association with FIB

The presence of HSYA, paeoniflorin, ferulic acid, ligustrazine, and ligustilide was detected using HPLC analysis. Additionally, muscone was identified through GC analysis as depicted in Figure 9A–H. Hence, it can be inferred that the potential inhibitory effect of TQHXD on neuroinflammation might be attributed to the aforementioned active ingredients- HSYA, paeoniflorin, ferulic acid, ligustrazine and muscone. Furthermore, molecular docking predictions for each component detected with FIB revealed that the binding energies of the five components with FIB were all below −5 kcal/mol (Figure 9I).

To investigate whether TQHXD could attenuate the accumulation of FIB in brain tissue, an ELISA was employed to quantify FIB levels. Following MCAO/R injury, disruption of the BBB was observed, accompanied by a significant increase in FIB levels. However, TQHXD treatment effectively restored BBB integrity and markedly reduced FIB deposition (Figure 9J). Western blot analysis further showed that TQHXD significantly reduced the expression levels of FIB (Figure 9K,L). The aforementioned results demonstrate that TQHXD possesses the requisite material foundation to interact with FIB.



Figure 9. TQHXD significantly downregulates the expression of FIB. ((**A**–**H**) The HPLC results were obtained based on the chemical composition of TQHXD. (**I**) The molecular docking results of the active ingredients of TQHXD and FIB. (**J**) TQHXD reduces the content of FIB in brain tissue. (n = 6). (**K**,**L**) The expression of FIB proteins was downregulated by TQHXD, as evidenced by Western blot experiments (n = 3).) ** $p < 0.01$ vs. Sham group; $^{\#\#}$ $p < 0.01$ vs. Model group.

3. Discussion

Neuroinflammation plays a pivotal role throughout the entire pathological course of IS and represents a key pathophysiological mechanism contributing to neuronal cell death [10,11]. It also constitutes a critical target for mitigating ischemic brain injury. Accumulating evidence indicates that upon initiation of the inflammatory response, activated brain cells release pro-inflammatory cytokines and ROS. While the early, transient inflammatory upregulation may exert neuroprotective effects, sustained or excessive inflammatory stimulation triggers a cascade of detrimental events. These include disruption of the BBB, loss of its functional integrity, and subsequent infiltration of peripheral immune cells into the central nervous system, ultimately leading to secondary neural damage [12,13]. Therefore, precise modulation of the inflammatory response holds significant therapeutic potential for improving functional recovery, reducing disability, and lowering mortality rates in patients with IS. Microglia represent the primary cellular component responsible for immune surveillance within the CNS. Under physiological conditions, microglia exhibit a ramified morphology characterized by small cell bodies and highly branched processes [14]. These dynamic processes enable microglia to continuously monitor alterations in the CNS microenvironment and promptly eliminate apoptotic neurons through efficient phagocytic activity. During cerebral ischemia, microglial cell bodies undergo hypertrophy, their processes become thickened, and they adopt an amoeba-like morphology, migrating toward the site of injury. These activated microglia contribute to neuroinflammatory damage by secreting pro-inflammatory cytokines [15], and the release of such inflammatory mediators is closely associated with NLRP3 inflammasome-mediated pyroptosis.

The NLRP3-mediated pyroptosis pathway represents one of the principal classical pathways of pyroptosis, with its central mechanism revolving around the assembly and activation of the NLRP3 inflammasome [16]. The NLRP3 inflammasome consists of three core components: nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing protein 3 (NLRP3), apoptosis-associated speck-like protein containing a CARD (ASC), and pro-caspase-1, organized in a complex structure of NLRP3–ASC–pro-caspase-1. Upon exposure to pyroptotic stimuli, NLRP3 functions as a pattern recognition receptor by recognizing these signals and recruiting pro-caspase-1 via the adaptor protein ASC, leading to the formation of an active inflammasome complex and subsequent activation of caspase-1. Activated caspase-1 exerts dual enzymatic functions: first, it cleaves Gasdermin-D to release its N-terminal fragment (GSDMD-N), which possesses membrane-perforating activity. GSDMD-N translocates to the plasma membrane, where it oligomerizes to form pores, disrupting membrane integrity, inducing cell swelling and lysis, and facilitating the release of intracellular inflammatory mediators, thereby initiating an inflammatory cascade. Second, caspase-1 processes the inactive precursors pro-IL-1β and pro-IL-18 into their mature, bioactive forms-IL-1β and IL-18, which are then secreted extracellularly to recruit and activate various immune cells, thereby amplifying local or systemic inflammatory responses [17–19].

For patients with acute IS, intravenous administration of tissue plasminogen activator (tPA) within the therapeutic time window can effectively restore cerebral blood flow. However, this treatment may disrupt normal coagulation function, thereby increasing the risk of hemorrhagic complications and adversely affecting clinical outcomes [20]. Therefore, to enhance the safety of tPA therapy, close monitoring and proactive prevention of bleeding events during thrombolysis are essential. FIB, as a key protein involved in the coagulation cascade, serves as an important indicator of coagulation and fibrinolytic status, enabling clinicians to assess bleeding risk. Research has demonstrated that circulating FIB levels are closely associated with the severity of IS; elevated FIB concentrations correlate with more severe disease and poorer prognosis, which may be attributed to the exacerbation

of systemic inflammatory responses. We ~~first~~ examined the changes in FIB content in peripheral blood and damaged brain tissue. The FIB content in the peripheral blood of the Model group was significantly higher than that of the Sham group, and reached a peak on the 7th day (Figure 1A). The FIB content in the damaged brain tissue also showed the same trend (Figure 1B). BBB is an important intermediary between the circulatory system and the protected environment of the brain. Studies have shown that the occurrence of cerebrovascular diseases increases the permeability of the BBB [21]. The previous animal and cell models of our research group have also confirmed the increase in BBB permeability and the impairment of its function after ischemia–reperfusion injury [22,23]. At the histological level, serum proteins such as FIB, thrombin and albumin can permeate the damaged BBB and enter the brain parenchyma. The MCAO/R model mice exhibit significant inflammatory injury, as evidenced by neurobehavioral deficits, reduced cerebral blood flow, increased cerebral infarction volume, inflammatory cell infiltration in the ischemic penumbra (Figure 2), microstructural damage associated with pyroptosis, and activation of the NLRP3 inflammasome in microglia (Figures 3 and 4)—findings that are consistent with the clinical characteristics of IS. Based on the current literature, there is no evidence indicating that Lumbrokinase can directly target NLRP3. However, protein–protein docking, molecular dynamics simulation, and pull-down assays have confirmed that FIB entering the brain can directly interact with NLRP3, thereby exerting its biological effects (Figure 1). The observed improvement in pathological outcomes following the reduction of cerebral FIB levels suggests that FIB infiltration across the BBB after ischemia–reperfusion injury may trigger the activation of NLRP3 inflammasomes in microglia, thereby exacerbating neuroinflammatory damage. Conversely, reducing intracerebral FIB levels appears to suppress NLRP3 inflammasome activation in microglia and mitigate inflammatory injury associated with IS.

TCM has garnered increasing attention due to its extensive application in clinical settings. TQHXD, a formula originally prescribed by Qingren Wang during the Qing Dynasty for the treatment of thrombosis, has been previously investigated by our group. TQHXD has been shown to mitigate cell apoptosis in the MCAO/R rat model through modulation of the ASK1/MKK4/JNK signaling pathway [6]. Concurrently, TQHXD activates the PI3K/Akt/mTOR pathway, thereby reducing autophagy levels in brain microvascular endothelial cells (BMECs) following cerebral ischemia–reperfusion injury [8]. Furthermore, TQHXD promotes the proliferation, migration, and differentiation of neural stem cells, potentially via regulation of the BDNF-TrkB-PI3K-Akt signaling pathway [24]. Additionally, TQHXD ameliorates neuronal damage associated with cerebral ischemia-induced vascular dementia in rats by enhancing synaptic remodeling [25]. Following TQHXD intervention, the MCAO/R model mice exhibited significant improvements in neurological function, cerebral blood flow, brain edema, and cerebral infarction volume (Figure 5). Proteomics results demonstrated that TQHXD could significantly attenuate the MCAO/R-induced elevation of FIB in brain tissue. Furthermore, pathway enrichment analysis revealed a predominant association with the NLRP3 inflammasome signaling pathway (Figure 6), which aligns with the findings from our in vivo experiments. As well as in the ultrastructural integrity of cells within the ischemic penumbra and the activation status of NLRP3 inflammasomes in microglia, compared to the Model group (Figures 7 and 8). The primary active components of TQHXD were identified using HPLC, and molecular docking analysis between these compounds and FIB demonstrated strong binding affinities for all tested constituents. Changes in FIB content and expression levels in the ipsilateral brain tissue indicate that TQHXD effectively reduces intracerebral FIB concentration (Figure 9). Despite the aforementioned research advancements, this study has certain limitations due to temporal and contextual constraints. Currently, there is a scarcity of highly specific

inhibitors targeting FIB, with most existing therapeutic agents modulating fibrinogen levels or functions through indirect mechanisms rather than via direct and specific interaction with the fibrinogen molecule. In this study, earthworm kinase—selected based on existing literature—was employed to degrade FIB. Given that brain FIB originates from peripheral infiltration, the in vitro experiments conducted were limited to screening interventions at specific FIB concentrations and did not incorporate advanced molecular techniques such as gene silencing or overexpression. Future studies will focus on performing targeted gene knockout in murine models and integrating modern experimental approaches, including brain organoid systems, to expand the scope of investigation and enable a more comprehensive and mechanistically detailed understanding of FIB's role. Moreover, clarify the characteristics of TQHXD in exerting effects via multiple pathways and targeting multiple sites.

4. Methods

4.1. Animals

Male *C57BL/6* mice (150 males, 22–25 g) were obtained from Henan Skbex Biotechnology Co., Ltd. (Anyang, China). The animals were reared under regulated circumstances, accompanied by a room temperature of 25 °C and a relative humidity ranging from 52–54%. A light cycle of 12 h per day was maintained.

4.2. Drugs and Reagents

TQHXD consists of the following components in its formulation: *Moschus berezovskii* Flerov (0.15 g), *Prunus persica* (L.) Batsch (9 g), *Paeonia lactiflora* Pall. (3 g), *Ligusticum chuanxiong* (3 g), *Carthamus tinctorius* L. (9 g), and *Allium fistulosum* L. (14 g). The preparation was supplied by the Pharmacy at the First Affiliated Hospital of Anhui University of Chinese Medicine (Hefei, China). MCC950 (chemical formula: $C_{20}H_{24}N_2O_5S$; molecular weight: 404.48) was obtained from Sparkjade (Shandong Sparkjade Biotechnology Co., Ltd., Jinan, China), with a purity exceeding 98.33%, as confirmed by HPLC analysis. Lumbrokinase was sourced from Aladdin (Shanghai, China), with a stated purity of over 12,000 U/mg. NLRP3 antibodies (ab263899, ab309497) were acquired from Abcam (Cambridge, MA, USA), while GSDMD antibodies were provided by Proteintech Co., Ltd. (Wuhan, China). Hieff® Quick exosome isolation kit (for Cell Culture Media) was procured from Yeasen (Shanghai, China). The Mouse Fibrinogen (FIB) ELISA Kit (JL20600-96T) was purchased from Shanghai Jianglai Industrial Limited by Share Ltd. (Shanghai, China). Additionally, ASC (catalog number 340097), along with antibodies targeting GAPDH and β-actin, were obtained from ZENBIO (Zen Bioscience, Chengdu, China).

4.3. The Preparation of TQHXD

Weigh ten-fold the amount of the original formula of the medicinal materials. Then, add ten-fold the amount of 70% ethanol, soak the mixture for 2 h, and perform reflux extraction for 2 h. After that, filter the mixture. Next, add eight-fold the amount of 70% ethanol to the medicinal material residue and perform reflux extraction for 1.5 h. Combine the filtrates and concentrate them until there is no alcohol smell. Incorporate 1.5 g of artificial musk into the extract and adjust the volume to prepare an extract with a crude drug concentration of 2 g/mL.

4.4. Experimental Grouping and Drug Administration

Following seven days of adaptive feeding, the mice underwent middle cerebral artery occlusion and reperfusion (MCAO/R) to establish the model. Subsequently, the successfully modeled mice were randomly assigned to the following

groups: sham operation group (sham group), MCAO/R model group (MCAO/R group), Lumbrokinase treatment group (MCAO/R + 1 mg/kg Lumbrokinase group), and MCC950 treatment group (MCAO/R + 50 mg/kg MCC950 group), TQHXD groups (MCAO/R + 3.87 g/kg, MCAO/R + 7.7 g/kg, MCAO/R + 15.4 g/kg), and butylphthalide group (MCAO/R + 40 mg/kg NBP). TQHXD, Lumbrokinase and MCC950 were administered orally for 3, 7, and 14 days.

4.5. Establishment of Cerebral MCAO/R Model [26,27]

The cerebral MCAO/R model was established following Longa's suture method. After intraperitoneal injection of 40 mg/kg sodium pentobarbital for anesthesia, the mice were positioned supine and immobilized. The right-sided common carotid artery (CCA), external carotid artery (ECA), and internal carotid artery (ICA) were carefully exposed and dissected. Proximal ligation was performed on the CCA and ECA, although the ICA was occluded using a vascular clamp. A minor cut was created at the terminal portion of the common carotid artery, 0.165 mm nylon thread was inserted from the common carotid artery into the middle cerebral artery via the internal carotid artery. After 1 h, the nylon thread was slowly withdrawn to restore blood flow. In the sham-operated control group, all surgical procedures were performed in the same manner, with the exception that the middle cerebral artery was not cannulated or manipulated. Following surgery, mice were placed in a 37 $\pm$ 0.5 °C incubator until they regained consciousness. Neurobehavioral scores were assessed after 24 h.

4.6. Cerebral Blood Flow

The scalp was incised to fully expose it, and the probe was positioned directly above the mouse's skull in parallel alignment, followed by capturing images employing a laser speckle technique (RFLSI ZW, RWD, Shenzhen, China) for blood flow imaging as per instrument protocol. Finally, analysis software for flowmetry was employed to analyze cerebral blood perfusion in mice.

4.7. Neurobehavioral Score and TTC Staining

The neurological function of mice was evaluated using the Longa scoring system [28]: 0, no evident behavioral changes; 1, flexion of the left forelimb and extension of the left hind limb; 2, rear-end on the left; 3, walking difficulties and shaking; 4, absence of spontaneous activity and disturbance of consciousness. Brain tissue sections were incubated at 37 °C for 30 min and then stained with TTC to assess the extent of cerebral infarction using Image J 10.0 software.

4.8. Proteomics

The Proteomics MCAO/R animal models were established and categorized into three groups: sham-operation group, model group, and TQHXD optimal dose group. The experimental procedure involved protein extraction, quality control assessment, enzymatic salt removal, and fractionation. Subsequently, LC-MS/MS mass spectrometry was conducted, followed by loading the DIA samples onto a computer for analysis. Spectronaunt software (Switzerland) was employed to perform a database search using *Mus musculus* (Mouse) as the reference species for data analysis. Finally, the identified protein results were obtained.

4.9. Hematoxylin and Eosin Staining (HE Staining)

The brains of mice were removed following anesthesia perfusion, and paraffin sections were prepared. After routine deparaffinization, 5 μm thick coronal sections were obtained and subjected to HE staining. The brains were fixed in 4% (*w*/*v*) PFA in PBS, sectioned,

and immersed in PBS for 3 min. Then, they were stained with hematoxylin for 5 min and rinsed with water for 1 min. To differentiate the tissue sections, they were treated with 1% hydrochloric acid for 10 s followed by washing with water for 1 min. Next, the sections underwent blue staining using 1% ammonia solution for 30 s before being washed again with water for another half a minute. Afterwards, the tissue was stained with eosin at a concentration of 0.5% for a duration of two minutes, followed by another water wash step lasting half a minute. Finally, elution was performed using gradient ethanol, and the sealed tissue sections were photographed under a light microscope.

4.10. Transmission Electron Microscopy

The brain tissues of mice were fixed in a 2.5% glutaraldehyde solution, followed by post-fixation in 1% osmic acid. The samples were dehydrated using a graded ethanol series, culminating in treatment with anhydrous ethanol. The dehydrated samples were embedded in epoxy resin. And subjected to dual staining with uranyl acetate and lead citrate prior to examination under a transmission electron microscope (JEM-1230, JEOL, Tokyo, Japan).

4.11. Immunofluorescence Staining

The mouse brains were fixed for 24 h and then stored in a freezing microtome solution containing 30% sucrose/PBS. Coronal sections, measuring 20 microns thick, were prepared on slides. IF staining was conducted using the appropriate primary antibodies. Following four sequential 7 min rinses in PBS, the sections underwent incubation with secondary antibodies, subsequently followed by a 12 min treatment with DAPI and an additional four PBS washes. Once air-dried, the sections were carefully mounted onto slides using mounting medium and covered with glass coverslips for subsequent microscopic observation and photography.

4.12. Enzyme-Linked Immunosorbent Assay (ELISA)

The levels of FIB in plasma and brain tissue were quantified using an ELISA kit. Following the instructions provided, a standard curve was generated by plotting the concentration of the standard against its corresponding optical density (OD) value at 450 nm wavelength. The OD values of the samples were measured and used to calculate their respective concentrations.

4.13. Western Blot

After extracting the samples from each group, they were lysed using RIPA lysate, and the protein concentration of each group was determined using a BCA quantification kit. Subsequently, protein samples from each group were separated by SDS-PAGE electrophoresis and transferred onto PVDF membranes. Following blocking with 5% skim milk powder for 1 h at room temperature, the cells were incubated overnight at 4 °C with their respective primary antibodies. On the following day, the membranes were rinsed and incubated with an HRP-labeled secondary antibody (diluted to 1:10,000) for 1 h at 37 °C. After another round of rinsing, the gel imaging system was activated to detect signals using an enhanced chemiluminescence (ECL) kit (Sparkjade, Jinan, China), and subsequently analyzed using Image J 10.0 software.

4.14. Molecular Dynamics Simulation

This study utilized GROMACS 2022 for conducting molecular dynamics simulations. The receptor protein was modeled by means of the AMBER14SB force field. Meanwhile, the topology of the ligand's GAFF2 force field was generated through sobtop_1.0 (dev3.1), and charges were assigned by applying the RESP method. The system was solvated

within a 1 nm cubic water box employing the TIP3P water model, and 0.15 M NaCl was added to neutralize the charge. Electrostatic interactions were addressed using the PME method, with a cutoff radius of 1 nm, and bond constraints were managed via the LINCS algorithm. Prior to the simulation, the system sequentially underwent three stages of energy minimization: constrained solute, constrained ions, and unconstrained full system, amounting to a total of 5000 steps. The formal simulation was performed under the NPT ensemble, with a temperature of 310 K (regulated by the Nosé–Hoover thermostat) and a pressure of 1 bar (regulated by the Parrinello–Rahman barostat), an integration step of 2 fs, and a simulation duration of 100 ns. Trajectory analysis was carried out using the built-in tools of GROMACS to compute root mean square deviation (RMSD), root mean square fluctuation (RMSF), hydrogen bonds, radius of gyration (Rg), solvent accessible surface area (SASA), and free energy landscape, so as to assess structural stability and dynamic behavior.

4.15. Statistical Analysis

The experimental results were expressed as mean ± standard deviation. Statistical analysis was performed using SPSS software (Version 23.0, SPSS Inc., Chicago, IL, USA). Multi-group comparisons were evaluated using ANOVA, followed by Fisher's Least Significant Difference (LSD) post hoc test to identify significant differences between groups. A p-value of less than 0.05 was considered statistically significant.

5. Conclusions

Inflammation is triggered following MCAO/R injury and exacerbates brain damage by inducing microglial pyroptosis through the FIB-NLRP3 signaling pathway in MCAO/R, whereas TQHXD counteracts this phenomenon. Subsequent research will persist in concentrating on the core pathogenesis of "blood stasis syndrome" and the FIB-NLRP3 pathway. By establishing a "blood stasis-ischemia" composite model in FIB gene knockout mice and integrating modern experimental techniques such as organoid culture, the molecular mechanism of "syndrome differentiation and treatment" of TQHXD will be further explored, and the experimental evidence system for the integrated traditional Chinese and Western medicine intervention in IS will be enhanced.

Author Contributions: C.W. and N.W. directed our study. Y.W. and H.S. executed most of the experimental operations. Y.P. and K.Z. contributed to parts of the data analyses. C.W. edited the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the project "Basic Research on the Application of Chinese Medicinal Formulas in Preventing and Treating Encephalopathy," supported by the Outstanding Research and Innovation Team Program of Anhui Province Universities (Anhui Provincial Department of Education, Grant No. 2022AH010034). Additionally, it was supported by a key project under the 2023 Natural Science Research Fund for Universities in Anhui Province (Grant No. 2023AH050738).

Institutional Review Board Statement: All animal protocols were approved by the Experimental Animal Ethics Committee of Anhui University of Traditional Chinese Medicine (ethics batch numbers: AHUCM-mouse-2024105 and AHTCM-rat-2024106) on 13 November 2024.

Informed Consent Statement: Not applicable.

Data Availability Statement: The raw data supporting the conclusions of this article will be made available by the authors on request.

Conflicts of Interest: The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:

ASC	Apoptosis-Associated Speck-like Protein Containing a CARD.
BBB	Blood–brain barrier.
CIRI	Cerebral ischemia–reperfusion injury.
FIB	Fibrinogen.
GSDMD	Gasdermin-D.
HE	Hematoxylin–Eosin.
HSYA	Hydroxysafflor yellow A.
IS	Ischemic Stroke.
IL-**1β**	Interleukin-1 beta.
IL-**18**	Interleukin-**18**
MCAO/R	Middle cerebral artery occlusion/reperfusion.
NLRP3	NOD-like receptor thermal protein domain-associated protein 3.
NBP	N-Butylphathlide.
TQHXD	Tong-Qiao-Huo-Xue Decoction.
TTC	2,3,5-Triphenyltetrazolium Chloride.

References

1. Han, B.; Zhou, S.; Zhang, Y.; Chen, S.; Xi, W.; Liu, C.; Zhou, X.; Yuan, M.; Yu, X.; Li, L.; et al. Integrating spatial and single-cell transcriptomics to characterize the molecular and cellular architecture of the ischemic mouse brain. *Sci. Transl. Med.* **2024**, *16*, eadg1323. [CrossRef]
2. Diprose, W.K.; Diprose, J.P.; Wang, M.T.M.; Tarr, G.P.; McFetridge, A.; Barber, P.A. Automated Measurement of Cerebral Atrophy and Outcome in Endovascular Thrombectomy. *Stroke* **2019**, *50*, 3636–3638. [CrossRef] [PubMed]
3. Candelario-Jalil, E.; Dijkhuizen, R.M.; Magnus, T. Neuroinflammation, Stroke, Blood-Brain Barrier Dysfunction, and Imaging Modalities. *Stroke* **2022**, *53*, 1473–1486. [CrossRef] [PubMed]
4. Li, W.; Shen, N.; Kong, L.; Huang, H.; Wang, X.; Zhang, Y.; Wang, G.; Xu, P.; Hu, W. STING mediates microglial pyroptosis via interaction with NLRP3 in cerebral ischaemic stroke. *Stroke Vasc. Neurol.* **2024**, *9*, 153–164. [CrossRef]
5. Roseborough, A.D.; Zhu, Y.; Zhao, L.; Laviolette, S.R.; Pasternak, S.H.; Whitehead, S.N. Fibrinogen primes the microglial NLRP3 inflammasome and propagates pro-inflammatory signaling via extracellular vesicles: Implications for blood-brain barrier dysfunction. *Neurobiol. Dis.* **2023**, *177*, 106001. [CrossRef]
6. Yuan, M.; Zhang, Y.; Wang, L.; Hua, Y.; Wang, Y.; Cheng, H.; Wang, N.; Wang, G.; Seto, S. Study on the mechanism of Tong-Qiao-Huo-Xue decoction regulating apoptosis via ASK1/MKK4/JNK pathway in MCAO/R rats. *Phytomed. Int. J. Phytother. Phytopharm.* **2022**, *106*, 154437. [CrossRef]
7. Li, L.; Wang, N.; Jin, Q.; Wu, Q.; Liu, Y.; Wang, Y. Protection of Tong-Qiao-Huo-Xue Decoction against Cerebral Ischemic Injury through Reduction Blood-Brain Barrier Permeability. *Chem. Pharm. Bull.* **2017**, *65*, 1004–1010. [CrossRef]
8. Hua, Y.; Zhai, Y.; Wang, G.; Wang, N.; Wu, Q.; Huang, Q.; Seto, S.; Wang, Y. Tong-Qiao-Huo-Xue decoction activates PI3K/Akt/mTOR pathway to reduce BMECs autophagy after cerebral ischemia/reperfusion injury. *J. Ethnopharmacol.* **2022**, *298*, 115585. [CrossRef]
9. Zhang, F.; Zhai, M.; Wu, Q.; Jia, X.; Wang, Y.; Wang, N. Protective Effect of Tong-Qiao-Huo-Xue Decoction on Inflammatory Injury Caused by Intestinal Microbial Disorders in Stroke Rats. *Biol. Pharm. Bull.* **2020**, *43*, 788–800. [CrossRef] [PubMed]
10. Zhang, W.; Tian, T.; Gong, S.X.; Huang, W.Q.; Zhou, Q.Y.; Wang, A.P.; Tian, Y. Microglia-associated neuroinflammation is a potential therapeutic target for ischemic stroke. *Neural Regen. Res.* **2021**, *16*, 6–11. [CrossRef]
11. Chang, N.C.; Yeh, C.T.; Lin, Y.K.; Kuo, K.T.; Fong, I.H.; Kounis, N.G.; Hu, P.; Hung, M.Y. Garcinol Attenuates Lipoprotein(a)-Induced Oxidative Stress and Inflammatory Cytokine Production in Ventricular Cardiomyocyte through α7-Nicotinic Acetylcholine Receptor-Mediated Inhibition of the p38 MAPK and NF-κB Signaling Pathways. *Antioxidants* **2021**, *10*, 461. [CrossRef]
12. Zhang, D.; Qian, J.; Zhang, P.; Li, H.; Shen, H.; Li, X.; Chen, G. Gasdermin D serves as a key executioner of pyroptosis in experimental cerebral ischemia and reperfusion model both in vivo and in vitro. *J. Neurosci. Res.* **2019**, *97*, 645–660. [CrossRef]
13. Zhang, L.; Liu, H.; Jia, L.; Lyu, J.; Sun, Y.; Yu, H.; Li, H.; Liu, W.; Weng, Y.; Yu, W. Exosomes Mediate Hippocampal and Cortical Neuronal Injury Induced by Hepatic Ischemia-Reperfusion Injury through Activating Pyroptosis in Rats. *Oxidative Med. Cell. Longev.* **2019**, *2019*, 3753485. [CrossRef]
14. Prinz, M.; Jung, S.; Priller, J. Microglia Biology: One Century of Evolving Concepts. *Cell* **2019**, *179*, 292–311. [CrossRef]

15. Wang, Q.; Yang, W.; Zhang, J.; Zhao, Y.; Xu, Y. TREM2 Overexpression Attenuates Cognitive Deficits in Experimental Models of Vascular Dementia. *Neural Plast.* **2020**, *2020*, 8834275. [CrossRef] [PubMed]
16. Chai, Y.; Cai, Y.; Fu, Y.; Wang, Y.; Zhang, Y.; Zhang, X.; Zhu, L.; Miao, M.; Yan, T. Salidroside Ameliorates Depression by Suppressing NLRP3-Mediated Pyroptosis via P2X7/NF-κB/NLRP3 Signaling Pathway. *Front. Pharmacol.* **2022**, *13*, 812362. [CrossRef] [PubMed]
17. Liang, J.; Wang, Q.; Li, J.Q.; Guo, T.; Yu, D. Long non-coding RNA MEG3 promotes cerebral ischemia-reperfusion injury through increasing pyroptosis by targeting miR-485/AIM2 axis. *Exp. Neurol.* **2020**, *325*, 113139. [CrossRef] [PubMed]
18. Heilig, R.; Dick, M.S.; Sborgi, L.; Meunier, E.; Hiller, S.; Broz, P. The Gasdermin-D pore acts as a conduit for IL-1β secretion in mice. *Eur. J. Immunol.* **2018**, *48*, 584–592. [CrossRef]
19. Shen, H.; Han, C.; Yang, Y.; Guo, L.; Sheng, Y.; Wang, J.; Li, W.; Zhai, L.; Wang, G.; Guan, Q. Pyroptosis executive protein GSDMD as a biomarker for diagnosis and identification of Alzheimer's disease. *Brain Behav.* **2021**, *11*, e02063. [CrossRef]
20. Vandelli, L.; Marietta, M.; Trenti, T.; Varani, M.; Bigliardi, G.; Rosafio, F.; Dell'acqua, M.L.; Picchetto, L.; Nichelli, P.; Zini, A. Fibrinogen concentrate replacement in ischemic stroke patients after recombinant tissue plasminogen activator treatment. *Adv. Clin. Exp. Med. Off. Organ Wroc. Med. Univ.* **2019**, *28*, 219–222. [CrossRef]
21. Verheggen, I.C.M.; de Jong, J.J.A.; van Boxtel, M.P.J.; Postma, A.A.; Jansen, J.F.A.; Verhey, F.R.J.; Backes, W.H. Imaging the role of blood-brain barrier disruption in normal cognitive ageing. *GeroScience* **2020**, *42*, 1751–1764. [CrossRef]
22. Roseborough, A.D.; Rasheed, B.; Jung, Y.; Nishimura, K.; Pinsky, W.; Langdon, K.D.; Hammond, R.; Pasternak, S.H.; Khan, A.R.; Whitehead, S.N. Microvessel stenosis, enlarged perivascular spaces, and fibrinogen deposition are associated with ischemic periventricular white matter hyperintensities. *Brain Pathol.* **2022**, *32*, e13017. [CrossRef]
23. McAleese, K.E.; Graham, S.; Dey, M.; Walker, L.; Erskine, D.; Johnson, M.; Johnston, E.; Thomas, A.J.; McKeith, I.G.; DeCarli, C.; et al. Extravascular fibrinogen in the white matter of Alzheimer's disease and normal aged brains: Implications for fibrinogen as a biomarker for Alzheimer's disease. *Brain Pathol.* **2019**, *29*, 414–424. [CrossRef] [PubMed]
24. Peng, Y.; Sun, H.; Xu, F.; Ye, H.; Wang, Y.; Zhou, X.; Chang, D.; Wang, N.; Huang, P. Activation of BDNF-TrkB-PI3K-AKT signaling pathway by Tong-Qiao-Huo-Xue Decoction facilitates nerve regeneration and mitigates cerebral ischemia-reperfusion injury. *Phytomed. Int. J. Phytother. Phytopharm.* **2025**, *145*, 156966. [CrossRef] [PubMed]
25. Li, J.; Ye, H.; Xu, F.; Yang, Y.; Ge, C.; Yao, M.; Huang, P.; Wang, L.; Wang, N.; Zhou, X.; et al. Tong-Qiao-Huo-Xue Decoction promotes synaptic remodeling via cAMP/PKA/CREB pathway in vascular dementia rats. *Phytomed. Int. J. Phytother. Phytopharm.* **2024**, *135*, 156166. [CrossRef]
26. Huang, P.; Wu, S.P.; Wang, N.; Seto, S.; Chang, D. Hydroxysafflor yellow A alleviates cerebral ischemia reperfusion injury by suppressing apoptosis via mitochondrial permeability transition pore. *Phytomed. Int. J. Phytother. Phytopharm.* **2021**, *85*, 153532. [CrossRef]
27. Yao, M.; Liu, Y.; Meng, D.; Zhou, X.; Chang, D.; Li, L.; Wang, N.; Huang, Q. Hydroxysafflor yellow A attenuates the inflammatory response in cerebral ischemia-reperfusion injured mice by regulating microglia polarization per SIRT1-mediated HMGB1/NF-κB signaling pathway. *Int. Immunopharmacol.* **2025**, *147*, 114040. [CrossRef]
28. Longa, E.Z.; Weinstein, P.R.; Carlson, S.; Cummins, R. Reversible middle cerebral artery occlusion without craniectomy in rats. *Stroke* **1989**, *20*, 84–91. [CrossRef] [PubMed]